This is a non-core endpoint: only basic statistics are computed.
Endpoint definition
↥
FinnGen phenotype data
429209 individuals
Apply sex-specific rule None
429209
Check conditions None
429209
Check pre-conditions, main-only, mode, registry filters
Medicine purchases: ATC
L04AB02
1 out of 7 registries used, show all original rules.
16
Check minimum number of events
Min. number of events
3
16
Include endpoints None
16
Remove individuals based on genotype QC
16
RX_L04AB02
Control definitions
Control exclude
RX_L04AB
Extra metadata
First used in FinnGen datafreeze
DF4
Not enough data for upset plot.
Or the full data table
Similar endpoints
↥List of similar endpoints to
Infliximab
based on the number of shared cases.
Broader endpoints:
- Tumor necrosis factor alpha inhibitors
- Biological medication for rheuma
- ILD medications: immunosuppressive drugs
- ILD medications
- Any reimbursement code in KELA
Narrower endpoints:
None
Summary Statistics
↥Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 16 | 11 | 5 |
| Unadjusted prevalence (%) | 0.00 | 0.00 | 0.00 |
| Mean age at first event (years) | 44.33 | 45.61 | 41.53 |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: RX_L04AB02 – Infliximab
GWS hits:
Survival analyses between endpoints
↥Not a core endpoint, no data to show.
Drugs most likely to be purchased after Infliximab
↥Endpoint not on priority list, no data to show.